W. Thorpe Mckenzie

All filings by W. Thorpe Mckenzie on record concern XBiotech Inc., in the capacity of board member. The record holds 50 filings, for trades running from 25 November 2015 to 16 December 2021.

The open-market side counts 14 purchases for €645k alongside 20 sales for €7.5M. Sales outweigh purchases by €6.8M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant and 3 option exercises.

Half of the purchases are above €39k and half below. Clusters matter here: 1 out of 12 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Looking at 12 purchases old enough to measure, the stock rose over the following 90 days in 58% of cases; the median change was +12.2%. Past outcomes like these are no guarantee of what comes next.

Most recently, on 13 January 2022, the filings show a share grant worth €2.2M in XBiotech Inc. The clock since the last published purchase (4 March 2019) now reads 2,806 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.